**Curriculum Vitae of Mohammad Reza Haghshenas**

**(Last Update: 12.05.2023)**

****

**First Name:** Mohammad Reza

**Surname:** Haghshenas

**Current position:** Assistant professorof Immunology

**Address:** Proteomics and biomarker lab**,** Shiraz Institute for Cancer Research, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

 Tel: 711-32303687- 9173810029
 Fax: 711-32304952
 E-mail: haghshenasmr@sums.ac.ir , vhaghshenas@yahoo.com, vhaghshenasmr@gmail.com

**Personal Data:**

**Date of Birth:** 1979
**Place of Birth:** Larestan, Iran

**Residency:** Shiraz, Iran
**Marital Status:** Married

**Child:** 2

**Education:**

1. BSc. Degree in Medical Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. (Score Number: 18.1).

 2. MSc. Degree in Immunology, Mashhad & Shiraz University of Medical Sciences,Iran,

 May 2007 (Score Number: 18.55).

3. PhD by Research in Immunology, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran. June 2017 (Score Number: 19.62).

**Thesis Title**:

Proteomic and immunological dissection of malignant and benign salivary gland tumors: Serum and mesenchymal stem cell proteomics, lymphocyte subsets, chemokines and chemokine receptors

**Published papers from PhD thesis:**

1. Immune regulatory cells and IL17-producing lymphocytes in patients with benign

malignant salivary gland tumors, Immunology Letters, 2015, Impact factor:2.436

1. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors, Oral Diseases, 2016, Impact Factor: 2.31
2. Chemokine and chemokine receptor patterns in patients with benign and malignant salivary

gland tumors: a distinct role for CCR7, Eur. Cytokine Netw. 2017, Impact factor: 2.3

**Honors during education:**

1. Honor Student of BSc, Shahid Beheshti University of Medical Science, Tehran, Iran.
2. Honor MSc student of Immunology Department, Mashhad University of Medical Science, Mashhad, Iran.

**Published Papers:**

 (1-51)

1. Tabaei S, Haghshenas MR, Webster TJ, Ghaderi A. Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources. Analytical biochemistry. 2023;666:115074.

2. Tabaei S, Haghshenas MR, Ariafar A, Gilany K, Stensballe A, Farjadian S, Ghaderi A. Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity. Clinical proteomics. 2023;20(1):28.

3. Molaei V, Fattahi MR, Haghshenas MR, Hosseini SY, Malekhosseini SA, Sarvari J. Polymorphism Analysis of Interleukin-18 and Interleukin-37 Genes in Hepatitis B Infections with Different Outcomes: A Preliminary Report from an Iranian Population. Asian Pac J Cancer Prev. 2023;24(2):411-6.

4. Haghshenas MR, Ghaderi H, Daneste H, Ghaderi A. Immunological and biological dissection of normal and tumoral salivary glands. Int Rev Immunol. 2023;42(2):139-55.

5. Gerdabi S, Asadian F, Kiani R, Khademi B, Haghshenas MR, Erfani N. Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment. Head and neck pathology. 2023;17(1):178-92.

6. Aliabadi A, Haghshenas MR, Kiani R, Koohi-Hosseinabadi O, Purkhosrow A, Pirsalami F, Panjehshahin MR, Erfani N. In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning. Naunyn-Schmiedeberg's archives of pharmacology. 2023.

7. Saadati Z, Haghshenas MR, Rezaeifard S, Heidari F, Erfani N. Reference Ranges of Lymphocyte Subsets in Healthy Individuals from Southern Iran. Clinical laboratory. 2022;68(10).

8. Rezaei S, Azarpira N, Koohpeyma F, Yousefi R, Doaei S, Heidari M, Gholamalizadeh M, Haghshenas MR, Mazloom Z. Evaluation of morphology and angiogenesis of breast cancer in BALB/c mice using trypsin inhibitor from Cucumis melo seeds. In vitro and in vivo study. Contemporary oncology (Poznan, Poland). 2022;26(3):204-19.

9. Nejabat S, Haghshenas MR, Farjadian S. Allergenome profiling of Vespa orientalis venom by serum IgE in patients with anaphylactic reaction to this hornet sting. Toxicon : official journal of the International Society on Toxinology. 2022;214:130-5.

10. Haghshenas MR, Zamir MR, Sadeghi M, Fattahi MJ, Mirshekari K, Ghaderi A. Clinical relevance and therapeutic potential of IL-38 in immune and non-immune-related disorders. Eur Cytokine Netw. 2022;33(3):54-69.

11. Haghshenas MR, Saffarian A, Khademolhosseini A, Dehghanian A, Ghaderi A, Sotoodeh Jahromi A. Simultaneous Increase in Serum Levels of IL-37 and IL-18 Binding Protein In Low-Grade and High-Grade Brain Tumors. Asian Pac J Cancer Prev. 2022;23(8):2851-6.

12. Haghshenas MR, Erfani N, Khansalar S, Khademi B, Ashraf MJ, Razmkhah M, Ghaderi A. Proteomics Study of Mesenchymal Stem Cell-Like Cells Obtained from Tumor Microenvironment of Patients with Malignant and Benign Salivary Gland Tumors. Cell Journal (Yakhteh). 2022;24(4):196-203.

13. Fattahi MJ, Haghshenas MR, Ghaderi A. Immunometabolism in bladder cancer microenvironment. Endocr Metab Immune Disord Drug Targets. 2022.

14. Davoud R, Mohammad Reza H, Mahdi S, Zahra M, Zohreh B, Abbas G. Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice. Iranian Journal of Allergy, Asthma and Immunology. 2022;0(0).

15. Haghshenas MR, Hosseini SR, Fattahi MJ, Malekzadeh M, Ariafar A, Ghaderi A. Elevated IL-37 Serum Levels in Patients with Transitional Cell Carcinoma of Bladder. Iran J Immunol. 2021;18(4):346-53.

16. Gheshlaghi A, Haghshenas MR, Safarpour AR, Hosseini SY, Fattahi MR, Sarvari J. IL-17 Genetic Variations Increase The Risk of Cirrhotic/Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection. Iran J Immunol. 2021;18(2):130-40.

17. Dabbaghmanesh MH, Rezaei B, Haghshenas MR, Montazeri-Najafabady N, Mohammadian Amiri R, Erfani N. CCR4 1014C/T and CCL22 16C/A Genetic Variations in the Iranian Patients with Thyroid Cancer. Middle East Journal of Cancer. 2021:-.

18. Aslani A, Haghshenas MR, Erfani N, Khezri AA. IL17A and IL17F Genetic Variations in Iranian Patients with Urothelial Bladder Cancer: A Case-Control Study. Middle East Journal of Cancer. 2021;12(3):377-82.

19. Shiri Z, Mansouri R, Haghshenas MR, Talei A, Erfani N. FOXP3 Genetic Variation at Position -2383 C/T (rs3761549) in Patients with Breast Cancer. Middle East Journal of Cancer. 2019;10(4):299-304.

20. Rostamzadeh D, Yousefi M, Haghshenas MR, Ahmadi M, Dolati S, Babaloo Z. mTOR Signaling pathway as a master regulator of memory CD8(+) T-cells, Th17, and NK cells development and their functional properties. Journal of cellular physiology. 2019;234(8):12353-68.

21. Rostamzadeh D, Haghshenas MR, Daryanoosh F, Samadi M, Hosseini A, Ghaderi A, Mojtahedi Z, Babaloo Z. Altered frequency of CD8(+) CD11c(+) T cells and expression of immunosuppressive molecules in lymphoid organs of mouse model of colorectal cancer. Journal of cellular physiology. 2019;234(7):11986-98.

22. Mohammadipour K, Mansouri R, Salmanpour R, Haghshenas MR, Erfani N. Investigation of Interleukin-17 Gene Polymorphisms and Serum Levels in Patients with Basal Cell Carcinoma of the Skin. Iran J Immunol. 2019;16(1):53-61.

23. Ghapanchi J, Ghaderi H, Haghshenas MR, Jamshidi S, Rezazadeh F, Azad A, Farzin M, Derafshi R, Kalantari AH. Observational Molecular Case-Control Study of Genetic Polymorphisms 1 in Programmed Cell Death Protein-1 in Patients with Oral Lichen Planus. Asian Pac J Cancer Prev. 2019;20(2):421-4.

24. Arash S, Amir T, Mohammad Reza H, Mousa T, Nooshafarin C, Abbas G, Mahboobeh R. Proteomics Study of Mesenchymal Stem Cell-Like Cells Isolated from Cerebrospinal Fluid of Patients with Meningioma. Current Proteomics. 2019;16(4):282-8.

25. Ghaderi H, Razmkhah M, Kiany F, Chenari N, Haghshenas MR, Ghaderi A. Comparison of Osteogenic and Chondrogenic Differentiation Ability of Buccal Fat Pad Derived Mesenchymal Stem Cells and Gingival Derived Cells. J Dent (Shiraz). 2018;19(2):124-31.

26. Pirdelkhosh Z, Kazemi T, Haghshenas MR, Ghayumi MA, Erfani N. Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer2017.

27. Namavar Jahromi F, Samadi M, Mojtahedi Z, Haghshenas MR, Taghipour M, Erfani N. Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients. Immunol Invest. 2017;46(5):469-80.

28. Haghshenas MR, Dabbaghmanesh MH, Miri A, Ghaderi A, Erfani N. Association of PDCD1 gene markers with susceptibility to thyroid cancer. Journal of endocrinological investigation. 2017;40(5):481-6.

29. Haghshenas MR, Ashraf MJ, Khademi B, Ghaderi A, Erfani N, Razmkhah M. Chemokine and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7. Eur Cytokine Netw. 2017;28(1):27-35.

30. Khademi B, Tajvarpour M, Mojtahedi Z, Haghshenas MR, Erfani N. T-helper Type 1 and 2 Cytokine Levels in Patients with Benign and Malignant Salivary Gland Tumors. Iran J Immunol. 2016;13(1):9-15.

31. Haghshenas MR, Khademi B, Ashraf MJ, Ghaderi A, Erfani N. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. Oral Dis. 2016;22(6):566-72.

32. Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, Erfani N. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. Immunol Lett. 2015;164(2):109-16.

33. Bina S, Shenavar F, Khodadad M, Haghshenas MR, Mortazavi M, Fattahi MR, Erfani N, Hosseini SY. Impact of RGD Peptide Tethering to IL24/mda-7 (Melanoma Differentiation Associated Gene-7) on Apoptosis Induction in Hepatocellular Carcinoma Cells. Asian Pac J Cancer Prev. 2015;16(14):6073-80.

34. Abdolahi F, Dabbaghmanesh MH, Haghshenas MR, Ghaderi A, Erfani N. A gene-disease association study of IL18 in thyroid cancer: genotype and haplotype analyses. Endocrine. 2015;50(3):698-707.

35. Ghapanchi J, Haghshenas MR, Ghaderi H, Amanpour S, Nemati V, Kamali F. Ctla-4 gene polymorphism in +49 a/g position: a case control study on patients with oral lichen planus. J Int Oral Health. 2014;6(5):17-21.

36. Faghih Z, Erfani N, Haghshenas MR, Safaei A, Talei AR, Ghaderi A. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2014;158(1-2):57-65.

37. Erfani N, Hamedi-Shahraki M, Rezaeifard S, Haghshenas M, Rasouli M, Samsami Dehaghani A. FoxP3+ regulatory T cells in peripheral blood of patients with epithelial ovarian cancer. Iran J Immunol. 2014;11(2):105-12.

38. Mojtahedi Z, Erfani N, Malekzadeh M, Haghshenas MR, Ghaderi A, Samsami Dehaghani A. HER2 Ile655Val Single Nucleotide Polymorphism in Patients with Ovarian Cancer. Iran Red Crescent Med J. 2013;15(1):1-3.

39. Mojtahedi Z, Erfani N, Haghshenas M, Hosseini S, Ghaderi A. Association of FoxP3/Scurfin Germline Polymorphism (C-2383T/rs3761549) with Colorectal Cancer. Ann Colorectal Res. 2013;1(1):0-.

40. Khandani M, Sedaghat T, Erfani N, Haghshenas MR, Khavasi HR. Synthesis, spectroscopic characterization, structural studies and antibacterial and antitumor activities of diorganotin complexes with 3-methoxysalicylaldehyde thiosemicarbazone. Journal of Molecular Structure. 2013;1037(0):136-43.

41. Erfani N, Khademi B, Haghshenas MR, Mojtahedi Z, Ghaderi A. Intracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma. Immunol Invest. 2013;42(2):81-90.

42. Erfani N, Moghaddasi-Sani F, Razmkhah M, Haghshenas MR, Talei A, Ghaderi A. CCL22 16C/a genetic variation is not associated with breast carcinoma in Southern Iranian population. Iran J Immunol. 2012;9(4):226-33.

43. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77(2):306-11.

44. Erfani N, Haghshenas MR, Hoseini MA, Hashemi SB, Khademi B, Ghaderi A. Strong association of CTLA-4 variation (CT60A/G) and CTLA-4 haplotypes with predisposition of Iranians to head and neck cancer. Iran J Immunol. 2012;9(3):188-98.

45. Yousefipour GA, Haghshenas MR, Yahyazadeh S, Erfani N. Stromal cell derived factor-1 genetic variation at locus 801 in patients with myasthenia gravis. Iran J Immunol. 2011;8(2):90-5.

46. Mojtahedi Z, Hashemi SB, Khademi B, Karimi M, Haghshenas MR, Fattahi MJ, Ghaderi A. p53 codon 72 polymorphism association with head and neck squamous cell carcinoma. Braz J Otorhinolaryngol. 2010;76(3):316-20.

47. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer. 2010;47(1):31-4.

48. Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep. 2010.

49. Shayan S, Abdi A, Zibaeenezhad M, Haghshenas M, Erfani N, Ghaderi A. Interleukin-18 Gene Polymorphism in Patients with and without

Atherosclerotic Coronary Artery Disease. Iranian Cardiovascular Research Journal. 2009;Vol.3, No.3,.

50. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol. 2009;24(6):1119-22.

51. Farjadfar A, Mojtahedi Z, Ghayumi MA, Erfani N, Haghshenas MR, Ghaderi A. Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol. 2009;48(7):971-6.

**Scopus citation:** Document h-index: 14

**Work Experience:**

1. Medical Technology in Emam Reza Hospital Laboratory (16 month).
2. Two years of work experience at "Bu-Ali Research Center" Mashhad University of Medical Science, Mashhad , Iran.
3. More than ten years of work experience at "Shiraz Institute for Cancer Research" Shiraz University of Medical Science, Shiraz, Iran.

**Technical Skills:**

1. Expert in different techniques of Flowcytometry
2. Expert in different methods of PCR (Arms, RFLP, Nested)
3. **Expert in proteomics studies (Conventional 2-DE and Mass analysis)**
4. Induction of breast and colon tumors in mouse model
5. Expert in techniques of gene and protein expression (Real time PCR and IHC)
6. Expert in cell culture and WST-1 technique
7. Familiar with sequencing techniques and bioinformatics analysis
8. Familiar with ELISA
9. Familiar with molecular techniques for study of cancers such as DNA extraction
10. Familiar with DNA bank

**Field of Interest:**

Cancer immunology, Biomarkers and cancer proteomics, Immunogenetics and molecular biology, Mesenchymal stem cells, Tumor mouse models.

**Computer Skills:**

1. Familiar with different skills of ICDL such as basic information, windows, internet, word, power point, excel, access

2. Expert in Flowcytometric analysis using CellQuest-Pro software packages.

3. Expert in Proteomics study and Protein Data base.

4. Familiar with Biostatistics software packages, including: SPSS and EpiInfo.

5. Expert in "EndNote" (reference managing) software packages.

**Holding and teaching at the workshops:**

1. Teaching at the Workshop entitled “Proteomics and Interpretation of Mass Spectrometry Results”, 14th International Congress of Immunology & Allergy of Iran, Shahid Beheshti, 2018, Tehran, Iran.
2. Practical teaching at summer school on the “Proteomics and Interpretation of Mass Spectrometry Results, 2018, Shiraz, Iran.
3. Practical teaching at the Workshop entitled “flowcytoetry, basics and applications”, Bushehr university of Medical Sciences, 2011, Bushehr, Iran.
4. Practical teaching at summer school on the “flowcytoetry, basics and applications”, , Shiraz university of Medical Sciences, Since 2013 to 2017, Shiraz, Iran.

**Invited Speaker:**

Clinical proteomics in cancer: a focus on personalized medicine, 2en international personalized Medicine Congress of Iran with Cancer Main topics, 13-15 January 2018, Razi International Congress Center, Tehran, Iran.

**Membership:**

 Representative of PhD by research at postgraduate student committee for two years

**International & National Congress:**

1. Comparison of protein expression pattern in different stages of breast cancer by two-dimensional electrophoresis and mass Spectrometry, Mohammad Reza Haghshenas, Zaynanb Mohammadi, Sedigheh Tahmasebi, Abbas Ghaderi (5th International Congress of Cancer, Shahid Beheshti University of Medical Sciences, Tehran, Iran).
2. Serum proteomics analysis in patients with tongue squamous cell carcinoma, Mohammad Reza Haghshenas Bijan Khademi, Abbas Ghaderi, (5th International Congress of Cancer, Shahid Beheshti University of Medical Sciences, Tehran, Iran).
3. Receiver Operating Characteristic curve analysis of IL-37 serum level in male patients with bladder cancer, Mohammad Reza Haghshenas1, Mohammad Javad Fattahi1, (5th International Congress of Cancer, Shahid Beheshti University of Medical Sciences, Tehran, Iran).
4. Increase in Helios-expressing regulatory T cells in lymph nodes of breast cancer mice treated with Everolimus, Mohammad Reza Haghshenas, Davood Rostam zadeh, Hossein Askarian Kakh, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz-Iran)
5. Effect of mTOR inhibitor everolimus  on Helios expression in CD4, CD8 and Treg cells isolated from spleen in a mouse model with breast cancer, Mohammad Reza Haghshenas, Davood Rostam zadeh, Iman Radmanesh, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
6. High expression of immune checkpoint molecules in different types of thyroid cancer,

Mahdi Sajedi Shacker, Mohammad Reza Haghshenas, Razieh Kiani, AmirReza Dehghanian, Nasrollah Erfani (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)

1. Elevated Interleukin-37 serum levels in patients with oral squamous cell carcinoma, Mohammad Reza Haghshenas, Hamid ghaderi, Soolmaz Khansalar, Mohammad Javad Fattahi, Hossain Shimardi, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
2. Elevated IL-37 serum levels in Iranian women with breast cancer , Mohammad Reza Haghshenas, Mohammad Javad Fattahi,Morteza Choobineh, Mahyar Malekzadeh, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
3. Increased serum concentrations of interleukin-37 in patients with bladder cancer , Mohammad Reza Haghshenas, Mohammad Javad Fattahi, Seyed Reza Hosseini1, [Ali Ariafar](https://journals.sums.ac.ir/?_action=article&au=199934&_au=Ali++Ariafar), Mahyar Malekzadeh, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
4. Investigation of serum level of IL-27 in endometrial cancer patients, Mohammad Javad Fattahi, Mohammad Reza Haghshenas, Ali Mohammad Karimi, Zahra Shiravani, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
5. Endocan serum levels in patients with low and high grade meningiomas: does this biomarker have an indicative role? Mohammad Javad Fattahi, Fatemeh Sedaghat, Mahyar Malekzadeh, Mohammad Reza Haghshenas , Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
6. Evaluation of lactate dehydrogenase and fatty acid synthase serum levels in bladder cancer patients, Mohammad Javad Fattah, Mohammad Reza Haghshenas, Ali Ariafar, Fatemeh Sedaghat, Mahyar Malekzadeh, Abbas Ghaderi (15th International Congress of Immunology & Allergy of Iran, Ahvaz -Iran)
7. Proteomic Pattern of Mesenchymal Stem Cells in the Patients with Malignant and Benign Salivary Gland Tumors, Mohammad Reza Haghshenas, Zahra Mojtahedi, Mahboobeh Razmkhah, Nasrollah Erfani, Bijan Khademi, Mohammad Javad Ashraf, Abbas Ghaderi (14th International Congress of Immunology & Allergy of Iran, Shahid Beheshti, Tehran -Iran)
8. Investigation of the gene polymorphism of CCL22 16C/A in patients with Basal Cell Carcinoma, Maryam Fakhimi, Sara Ghafarpour, Mohamad Reza Haghshenas, Faride Jowkar, Nasrollah Erfani (14th International Congress of Immunology & Allergy of Iran, Shahid Beheshti, Tehran -Iran)
9. Genetic variations of PD-1 co-inhibitory molecule (PD1.3and PD1.5) in patients with basal cell carcinoma, Maryam fakhimi, Maryam Abedi, Zahra Faghih, Mohammad Reza Haghshenas, Faride Jowkar, Nasrollah Erfani (14th International Congress of Immunology & Allergy of Iran, Shahid Beheshti, Tehran -Iran)
10. Investigation of natural killer (NK) and natural Killer T (NKT) lymphocytes in peripheral blood of patients with benign and malignant salivary gland tumors (13th International Congress of Immunology & Allergy of Iran, Tabriz -Iran)
11. Association of rs17568 polymorphism in OX40 gene with Basal cell carcinoma of skin(13th International Congress of Immunology & Allergy of Iran, Tabriz -Iran)

**15.** Helper and regulatory subsets of CD4+ lymphocytes in breast cancer tumor draining

lymph nodes. Erfani N, Faghih Z, Haghshenas MR, Safaei A, Talei AR, Ghaderi A

(12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

**16.** Th1 (IFN-γ) and Th2 (IL4) cytokines in salivary gland tumors

Erfani N, Khademi B, Tajvarpour M, Malekzadeh M, Haghshenas MR

(12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

**17**. Comparison between CYFRA 21-1 and CEA serum levels in Iranian patients with Nonsmall

cell lung cancer (NSCLC), Erfani N, Ghayoumi MA, Rafiee F, Deihimi S, Haghshenas MR, Malekzadeh M (12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

1. Retinol plasma level and its association with the percentage of regulatory T cells and

Th17 lymphocytes in patients with breast cancer, Erfani N, Mansouri R, Mansouri M, Talei AR, Faghih Z, Haghshenas MR (12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

1. Investigation of CCR4 and CCL22 genetic variants, respectively at positions C1014T &

C16A, with prostate cancer, Erfani N, Zeyghami SH, Hagghshenas MR, Javadi A, Aminfar R, Niakan A (12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

1. Imbalance of Th17 and FoxP3+ regulatory T cells in benign and malignant salivary gland

Tumors. Erfani N, Haghshenas MR, Khademi B, Faghih Z, Ghaderi A

(12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

1. PD1 genetic variations is associated with susceptibility to bladder cancer

Erfani N, Aminsharifi AR, Niakan A, Haghshenas MR, Bordbar S

Genetic polymorphisms of CCL22 and CCR4 in patients with lung cancer

Erfani N, Ghayumi M, Ahmadi S, Nedaei Ahmadi, Haghshenas M\*

(12th International Congress of Immunology & Allergy of Iran Milad Tower-Tehran-Iran)

1. IL-18 serum level in Iranian patients with GI cancer. Haghshenas MR,

 Mahmoudi M, Hossieni SV, Ghaderi A. Immunology Departments

of Shiraz and Mashhad University of Medical Sciences and Shiraz Institute

For Cancer Research, Shiraz, Iran. (10-14 SEPTEMBER, 2007,

MOSCOW, RUSSIA.)

**23**. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian

Patients with GI cancers. Haghshenas MR, Erfani N, Ghaderi A. Abstract Number: ABS2N-YRUTQ-3AAZL-B9PFZ for ASI 2007(Australian)).

 **24**. A systematic review to explain previous studies about the association between cytokine gene polymorphisms and breast cancer. Haghshenas MR , M.Sc 1, Rafatpanah H ,Ph.D 2 . Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran. 1 Bu-Ali Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2

( 3rd International Breast Cancer Congress. Shahid beheshti, Tehran, Iran.)

**25**. Stromal Cell Derived Factor1(SDF1) genetic variation at locus 801 is not associated with Myasthenia Gravis in Iranian population .

Mohammad Reza Haghshenas,Gholam Ali Yousefipour, Mohammad Reza Rajaie

Abbas Ghaderi ( The 9th congress of immunology and alergy, Tehran University of medical science, Tehran,Iran)

**26**. Detection of soluble HER-2 and its allele and genotype frequency in epithelial ovarian cancer. MohammadRezaHaghshenas, Sharareh Solati, Alamtaj Samsami,Mohammad javad Fattahi, Minoo Robati, Abbas Ghaderi

(The first International Gynecology Oncology Congress under the auspices of IGCS in Mashhad, Iran (10-12 Oct 2008)(oral presentation)

**27**. Program death 1(PD1)haplotyping in patients with breast cancer:

Nasrollah Erfani, Mohammad Reza Haghshenas, Sirous Naeimi, Abdol-rasoul Talei, Abbas Ghaderi. ( The 9th congress of immunology and alergy, Tehran University of medical science, Tehran,Iran.)

**28**. Evidences of Treg cells increase before metastasis in patients with non small cell lung cancer

Nasrollah Erfani, Mohammad Ali Ghayumi, Shayesteh Mofakhami Mehrabadi, Davar Amani, Mohammad Reza Haghshenas, Zahra Mojtahedi, Abbas Ghaderi (The 10th international congress of immunology and alergy, Shahid Beheshti University of medical science, Tehran,Iran.)

**29**. CTLA4 over-expression in intracellular compartments as well as on the surface of lymphocytes derived from patients with lung cancer

Shayesteh Mofakhami Mehrabadi, Davar Amani, Nasrollah Erfani, Mohammad Reza Haghshenas, Mohamma Ali Ghayumi, Abbas Ghadaeri

(The 10th international congress of immunology and alergy, Shahid Beheshti University of medical science, Tehran,Iran.)

**30**. Strong association of CTLA-4 variation (CT60A/G) and CTLA-4 haplotypes with predisposition of Iranian population to Head and Neck cancer

Nasrollah Erfani, Sayed Basir Hashemi, Mohammad Reza Haghshenas, Mohammad Ali Hosseni, Sirous Naeimi, Zahra Mojtahedi, Abbas Ghaderi (The 10th international congress of immunology and alergy, Shahid Beheshti University of medical science, Tehran,Iran.)

**31**. PD1.5 renders susceptibility to Head and Neck Squamous Cell Carcinoma

Bijan Khademi, Mohammad Reza Haghshenas, Tomaj Kaiedi, Nasrollah Erfani, , Zahra Mojtahedi, Abbas Ghaderi (The 10th international congress of immunology and alergy, Shahid Beheshti University of medical science, Tehran,Iran.)

**32**. Investigation of PD-1.5 genetic marker in colorectal cancer in Iranians

Nasrollah Erfani, Amirhossein Hadaegh, Mona Mohmadi Kartalaie, Elham Ashouri, Mohammad Reza Haghshenas, Abbas Ghadaeri (The 10th international congress of immunology and alergy, Shahid Beheshti University of medical science, Tehran,Iran.)

 **33**. IL-18 promoter variations at position -607 C/A is associated with individuals susceptibility to Basal Cell Carcinoma A.Kookhaei, S.Vakili, N.Erfani, M.Haghshenas, R.Salmanpour, A.Ghaderi. (14th International Congress of Immunology,22-27 August, 2010/Kobe,Japan)

**34**. The frequency of alleles and genotypes of programmed death (PD-1) in patients with colorectal cancer and its association with the diseases clinicopathological characteristics

Erfani N, Haghshenas MR, Mona Mohmedi Kartalai, Ghaderi A.(The 1st International student congress on cell and molecular medicine,Shiraz,Iran.)

**35**. CCR-4 variations at C1014T position in patients with Breast cancer . Moghaddasi F , Haghshenas MR , Ghaderi A, Erfani N, (The 1st International student congress on cell and molecular medicine,Shiraz,Iran.)

**36**. IL-18 serum level in Iranian patient with GI cancer. Haghshenas MR, Mahmoudi M, Hossieni SV, Ghaderi A. (2rd International GI Cancer Congress. Shahid beheshti, Tehran, Iran.)

**Referees:**

* 1. Dr. Abbas Ghaderi, Department of Immunology and Head of Institute for Cancer Research, Shiraz University of Medical Science, Shiraz, Iran.
	2. Dr. Nasrollah Erfani, PhD in Immunology, Department of Immunology and Shiraz Institute for Cancer Research, Shiraz, Iran.
	3. Dr. Mahmoud Mahmoudi, professor of Immunology Department and Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.